Clorazepate monopotassium

For research use only. Not for therapeutic Use.

  • CAT Number: I024985
  • CAS Number: 5991-71-9
  • Molecular Formula: C16H10ClKN2O3
  • Molecular Weight: 352.81
  • Purity: 98%
Inquiry Now

Clorazepate monopotassium(Cat No.:I024985)is a benzodiazepine medication primarily used to treat anxiety, seizures, and alcohol withdrawal symptoms. It works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity, promoting a calming effect. Clorazepate is often prescribed for short-term management of anxiety disorders and as part of seizure control regimens. It is also used as an adjunct therapy in alcohol withdrawal. Potential side effects include drowsiness, dizziness, and dependence with long-term use. It should be used under medical supervision to avoid withdrawal symptoms or overdose.


Catalog Number I024985
CAS Number 5991-71-9
Synonyms

Clorazepate monopotassium; Abbott-39083; Abbott 39083; Abbott39083

Molecular Formula C16H10ClKN2O3
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name potassium;7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylate
InChI InChI=1S/C16H11ClN2O3.K/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;/h1-8,14H,(H,18,20)(H,21,22);/q;+1/p-1
InChIKey ULEUKTXFAJZAAV-UHFFFAOYSA-M
SMILES C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)[O-].[K+]
Reference

1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Clorazepate. 2018 Oct 31. PMID: 30000269.
2: Hanna S, Diana F, Slevinski J, Veronich K, Lachman L. Differential pulse polarographic determination of clorazepate monopotassium and dipotassium. J Pharm Sci. 1978 Dec;67(12):1723-5. doi: 10.1002/jps.2600671224. PMID: 31451.
3: Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med. 1986 Mar 31;80(3B):10-6. doi: 10.1016/0002-9343(86)90326-8. PMID: 2870640.
4: Fujii T, Okuno T, Go T, Ochi J, Hattori H, Kataoka K, Mikawa H. Clorazepate therapy for intractable epilepsy. Brain Dev. 1987;9(3):288-91. doi: 10.1016/s0387-7604(87)80046-3. PMID: 2889387.
5: Elrod L Jr, Shada DM, Taylor VE. High-performance liquid chromatographic analysis of clorazepate dipotassium and monopotassium in solid dosage forms. J Pharm Sci. 1981 Jul;70(7):793-5. doi: 10.1002/jps.2600700721. PMID: 6115049.
6: Forrester SD, Brown SA, Lees GE, Hartsfield SM. Disposition of clorazepate in dogs after single- and multiple-dose oral administration. Am J Vet Res. 1990 Dec;51(12):2001-5. PMID: 2085227.
7: Bartenbach DE. Clorazepate dipotassium. Am Fam Physician. 1978 Oct;18(4):43,46,50. PMID: 30272.
8: Mimaki T, Tagawa T, Ono J, Tanaka J, Terada H, Itoh N, Yabuuchi H. Antiepileptic effect and serum levels of clorazepate on children with refractory seizures. Brain Dev. 1984;6(6):539-44. doi: 10.1016/s0387-7604(84)80097-2. PMID: 6152517.
9: Suzuki EM, Gresham WR. Identification of some interferences in the analysis of clorazepate. J Forensic Sci. 1983 Jul;28(3):655-82. PMID: 6137507.
10: Livingston S, Pauli LL. Clorazepate in epilepsy. JAMA. 1977 Apr 11;237(15):1561. PMID: 15140.

Request a Quote